AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has been given a consensus recommendation of “Hold” by the nine ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $5.00.
ACRX has been the subject of several analyst reports. Zacks Investment Research raised shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research report on Wednesday, December 27th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of AcelRx Pharmaceuticals in a research report on Friday, October 27th.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new stake in AcelRx Pharmaceuticals in the second quarter worth approximately $530,000. Geller Family Office Services LLC boosted its holdings in AcelRx Pharmaceuticals by 175.0% in the fourth quarter. Geller Family Office Services LLC now owns 275,000 shares of the specialty pharmaceutical company’s stock worth $557,000 after purchasing an additional 175,000 shares during the last quarter. Virtu KCG Holdings LLC boosted its holdings in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after purchasing an additional 101,742 shares during the last quarter. Virtu Financial LLC purchased a new stake in AcelRx Pharmaceuticals in the fourth quarter worth approximately $120,000. Finally, Perennial Advisors LLC purchased a new stake in AcelRx Pharmaceuticals in the third quarter worth approximately $138,000. 14.03% of the stock is owned by institutional investors.
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) traded down $0.02 during midday trading on Tuesday, hitting $1.88. 138,334 shares of the company’s stock were exchanged, compared to its average volume of 376,110. The company has a market capitalization of $94.81, a P/E ratio of -1.68 and a beta of 2.64. The company has a quick ratio of 4.71, a current ratio of 4.78 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a fifty-two week low of $1.55 and a fifty-two week high of $5.75.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/20/acelrx-pharmaceuticals-inc-acrx-given-average-rating-of-hold-by-brokerages.html.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.